NASDAQ:BGNE - BeiGene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$189.70 +1.84 (+0.98 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$189.70
Today's Range$185.4730 - $189.80
52-Week Range$36.51 - $202.88
Volume120,218 shs
Average Volume312,157 shs
Market Capitalization$10.10 billion
P/E Ratio-85.07
Dividend YieldN/A
Beta0.29

About BeiGene (NASDAQ:BGNE)

BeiGene logoBeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BGNE
CUSIPN/A
Phone34-59-494-12

Debt

Debt-to-Equity Ratio0.12
Current Ratio11.18
Quick Ratio11.12

Price-To-Earnings

Trailing P/E Ratio-85.07
Forward P/E Ratio-23.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$238.39 million
Price / Sales42.78
Cash FlowN/A
Price / CashN/A
Book Value$25.27 per share
Price / Book7.51

Profitability

EPS (Most Recent Fiscal Year)($2.23)
Net Income$-93,100,000.00
Net MarginsN/A
Return on Equity-19.12%
Return on Assets-13.75%

Miscellaneous

Employees900
Outstanding Shares53,760,000

BeiGene (NASDAQ:BGNE) Frequently Asked Questions

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How were BeiGene's earnings last quarter?

BeiGene (NASDAQ:BGNE) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.62) by $0.41. The firm had revenue of $32.54 million for the quarter, compared to analysts' expectations of $16.88 million. During the same period in the prior year, the business earned ($1.27) EPS. View BeiGene's Earnings History.

When is BeiGene's next earnings date?

BeiGene is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for BeiGene.

What price target have analysts set for BGNE?

9 analysts have issued twelve-month target prices for BeiGene's stock. Their forecasts range from $86.00 to $225.00. On average, they anticipate BeiGene's share price to reach $170.1667 in the next twelve months. View Analyst Ratings for BeiGene.

What are Wall Street analysts saying about BeiGene stock?

Here are some recent quotes from research analysts about BeiGene stock:
  • 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (5/14/2018)
  • 2. Maxim Group analysts commented, "BeiGene announced the commercial availability of Celgene’s VIDAZA. Recall that VIDAZA is an injectable nucleoside metabolic inhibitor for patients with Intermediate-2/high-risk myelodysplastic syndrome (MDS), AML with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). The asset is the third product in BeiGene’s China commercial portfolio along with Abraxane and Revlimid and positions BeiGene to be a leader in the oncology space in China." (2/7/2018)
  • 3. Cowen Inc analysts commented, "SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials." (11/14/2017)

Who are some of BeiGene's key competitors?

Who are BeiGene's key executives?

BeiGene's management team includes the folowing people:
  • Mr. John V. Oyler, Founder, Chairman and Chief Exec. Officer (Age 50)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board and Director (Age 55)
  • Dr. Heng Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 55)
  • Mr. Ji Li Ph.D., Exec. VP & Global Head of Bus. Devel. (Age 50)
  • Ms. Maggie Liu, Head of Operations and VP

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Has BeiGene been receiving favorable news coverage?

News headlines about BGNE stock have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BeiGene earned a media sentiment score of 0.13 on Accern's scale. They also gave headlines about the company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Temasek Holdings Private Ltd (4.22%), Artal Group S.A. (1.12%), OppenheimerFunds Inc. (1.07%), Indus Capital Partners LLC (1.05%), BlackRock Inc. (0.66%) and Prince Street Capital Management LLC (0.57%). Company insiders that own BeiGene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.

Which major investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Bellevue Group AG, DAFNA Capital Management LLC, Prince Street Capital Management LLC, Rock Springs Capital Management LP, State of New Jersey Common Pension Fund D, The Manufacturers Life Insurance Company and Employees Retirement System of Texas. Company insiders that have sold BeiGene company stock in the last year include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Insider Buying and Selling for BeiGene.

Which major investors are buying BeiGene stock?

BGNE stock was acquired by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, Artal Group S.A., KEYWISE CAPITAL MANAGEMENT Ltd, Indus Capital Partners LLC, Matthews International Capital Management LLC, Barings LLC, Hsbc Holdings PLC and Ariose Capital Management Ltd. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker and Thomas Malley. View Insider Buying and Selling for BeiGene.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $189.70.

How big of a company is BeiGene?

BeiGene has a market capitalization of $10.10 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. BeiGene employs 900 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]


MarketBeat Community Rating for BeiGene (BGNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BeiGene (NASDAQ:BGNE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for BeiGene in the last 12 months. Their average twelve-month price target is $170.1667, suggesting that the stock has a possible downside of 10.30%. The high price target for BGNE is $225.00 and the low price target for BGNE is $86.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.882.862.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $170.1667$166.00$93.00$93.00
Price Target Upside: 10.30% downside1.57% downside25.60% downside16.83% upside

BeiGene (NASDAQ:BGNE) Consensus Price Target History

Price Target History for BeiGene (NASDAQ:BGNE)

BeiGene (NASDAQ:BGNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Maxim GroupBoost Price TargetBuy$200.00 ➝ $225.00LowView Rating Details
5/14/2018Credit Suisse GroupInitiated CoverageOutperform ➝ OutperformHighView Rating Details
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$200.00MediumView Rating Details
3/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $200.00HighView Rating Details
3/1/2018Robert W. BairdReiterated RatingHold$138.00HighView Rating Details
3/1/2018Ladenburg ThalmannReiterated RatingBuy$172.00MediumView Rating Details
1/8/2018CowenReiterated RatingBuyHighView Rating Details
8/15/2017Goldman Sachs GroupReiterated RatingBuy$43.00 ➝ $86.00LowView Rating Details
6/1/2017William BlairReiterated RatingOutperformLowView Rating Details
(Data available from 5/26/2016 forward)

Earnings

BeiGene (NASDAQ:BGNE) Earnings History and Estimates Chart

Earnings by Quarter for BeiGene (NASDAQ:BGNE)

BeiGene (NASDAQ:BGNE) Earnings Estimates

2018 EPS Consensus Estimate: ($8.15)
2019 EPS Consensus Estimate: ($9.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.87)($1.87)($1.87)
Q2 20182($2.35)($2.15)($2.25)
Q3 20182($2.36)($2.15)($2.26)
Q4 20182($2.17)($1.38)($1.78)
Q1 20191($2.39)($2.39)($2.39)
Q2 20191($2.42)($2.42)($2.42)
Q3 20191($2.39)($2.39)($2.39)
Q4 20192($2.31)($2.30)($2.31)

BeiGene (NASDAQ BGNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($1.72)N/AView Earnings Details
5/9/2018Q1($1.62)($2.03)$16.88 million$32.54 millionViewN/AView Earnings Details
2/28/2018After Market($1.79)($2.19)$23.00 million$18.17 millionViewN/AView Earnings Details
11/13/2017Q3$0.23$2.54$1.55 million$220.21 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.21)($1.52)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.97)($1.27)ViewN/AView Earnings Details
3/22/2017Q4($0.86)($1.05)$3.75 million$1.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BeiGene (NASDAQ:BGNE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BeiGene (NASDAQ BGNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.90%
Institutional Ownership Percentage: 67.19%
Insider Trading History for BeiGene (NASDAQ:BGNE)
Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

BeiGene (NASDAQ BGNE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2018Howard LiangCFOSell40,000$160.27$6,410,800.0015,872View SEC Filing  
3/16/2018Howard LiangCFOSell10,872$157.07$1,707,665.0415,872View SEC Filing  
3/2/2018John OylerCEOSell99,000$145.63$14,417,370.0093,883View SEC Filing  
2/28/2018Ji LiEVPSell10,000$146.88$1,468,800.0010,000View SEC Filing  
2/28/2018John OylerCEOSell34,338$146.69$5,037,041.2293,883View SEC Filing  
1/18/2018Bros. Advisors Lp BakerDirectorBuy1,980,198$101.00$199,999,998.00View SEC Filing  
12/26/2017John OylerCEOSell20,137$96.46$1,942,415.02110,179View SEC Filing  
12/21/2017Jane HuangCMOSell1,000$98.00$98,000.001,000View SEC Filing  
12/13/2017Jane HuangCMOSell1,500$94.25$141,375.001,500View SEC Filing  
12/8/2017John OylerCEOSell144,000$93.95$13,528,800.00255,137View SEC Filing  
12/6/2017John OylerCEOSell31,446$92.29$2,902,151.34255,137View SEC Filing  
12/4/2017Jane HuangCMOSell1,100$86.00$94,600.00264,900View SEC Filing  
11/29/2017John OylerCEOSell85,906$84.66$7,272,801.96332,697View SEC Filing  
11/27/2017John OylerCEOSell16,581$86.76$1,438,567.56332,697View SEC Filing  
11/20/2017Jane HuangCMOSell1,600$86.25$138,000.00264,900View SEC Filing  
11/16/2017Jane HuangCMOSell600$85.00$51,000.00264,900View SEC Filing  
11/15/2017John OylerCEOSell150,957$80.50$12,152,038.50491,891View SEC Filing  
11/13/2017Amy C PetersonCMOSell3,601$82.96$298,738.961,201View SEC Filing  
11/13/2017John OylerCEOSell25,054$83.06$2,080,985.24491,891View SEC Filing  
8/11/2017Bros. Advisors Lp BakerDirectorBuy176,056$71.00$12,499,976.00View SEC Filing  
7/12/2017Xiaodong WangDirectorSell20,000$72.44$1,448,800.0016,300View SEC Filing  
7/10/2017Donald W GlazerDirectorSell10,810$72.15$779,941.507,206View SEC Filing  
7/6/2017John OylerCEOSell219,400$64.82$14,221,508.00212,055View SEC Filing  
6/28/2017Xiaodong WangDirectorSell35,000$44.95$1,573,250.0026,600View SEC Filing  
6/23/2017John OylerCEOSell98,500$44.16$4,349,760.0088,535View SEC Filing  
6/2/2017Xiaodong WangDirectorSell5,539$40.00$221,560.0055,000View SEC Filing  
5/4/2017Xiaodong WangDirectorSell14,461$40.80$590,008.8065,030View SEC Filing  
5/1/2017John OylerCEOSell36,149$40.47$1,462,950.03147,440View SEC Filing  
4/5/2017Xiaodong WangDirectorSell11,650$36.83$429,069.5081,194View SEC Filing  
3/24/2017Xiaodong WangDirectorSell38,107$36.96$1,408,434.72116,478View SEC Filing  
3/20/2017John OylerCEOSell31,989$39.39$1,260,046.71197,640View SEC Filing  
3/10/2017Xiaodong WangDirectorSell36,892$39.89$1,471,621.88150,657View SEC Filing  
3/6/2017John OylerCEOSell108,999$40.91$4,459,149.09273,385View SEC Filing  
2/27/2017Xiaodong WangDirectorSell38,351$38.19$1,464,624.69194,495View SEC Filing  
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65378,383View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.0030,000View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.584,881,997View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.894,881,997View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.864,881,997View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.844,882,000View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.0065,000View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00130,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BeiGene (NASDAQ BGNE) News Headlines

Source:
DateHeadline
BeiGene (BGNE) Expected to Post Quarterly Sales of $20.08 MillionBeiGene (BGNE) Expected to Post Quarterly Sales of $20.08 Million
www.americanbankingnews.com - May 26 at 4:41 AM
BeiGene (BGNE) Expected to Post Earnings of -$2.13 Per ShareBeiGene (BGNE) Expected to Post Earnings of -$2.13 Per Share
www.americanbankingnews.com - May 24 at 3:12 AM
Maxim Group Increases BeiGene (BGNE) Price Target to $225.00Maxim Group Increases BeiGene (BGNE) Price Target to $225.00
www.americanbankingnews.com - May 18 at 4:35 PM
BRIEF-Beigene Initiates Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian CancerBRIEF-Beigene Initiates Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian Cancer
www.reuters.com - May 17 at 9:43 AM
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian CancerBeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer
finance.yahoo.com - May 17 at 9:43 AM
BeiGene to Present at the 2018 UBS Global Healthcare ConferenceBeiGene to Present at the 2018 UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 4:49 PM
BeiGene (BGNE) Rating Lowered to Sell at Zacks Investment ResearchBeiGene (BGNE) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 14 at 7:04 PM
BeiGene (BGNE) Now Covered by Credit Suisse GroupBeiGene (BGNE) Now Covered by Credit Suisse Group
www.americanbankingnews.com - May 14 at 11:27 AM
Q2 2018 Earnings Estimate for BeiGene (BGNE) Issued By William BlairQ2 2018 Earnings Estimate for BeiGene (BGNE) Issued By William Blair
www.americanbankingnews.com - May 14 at 2:41 AM
Piper Jaffray Equities Analysts Decrease Earnings Estimates for BeiGene (BGNE)Piper Jaffray Equities Analysts Decrease Earnings Estimates for BeiGene (BGNE)
www.americanbankingnews.com - May 14 at 2:40 AM
BeiGene (BGNE) Given a $200.00 Price Target at Maxim GroupBeiGene (BGNE) Given a $200.00 Price Target at Maxim Group
www.americanbankingnews.com - May 10 at 7:51 PM
BeiGene (BGNE) Posts Quarterly  Earnings Results, Misses Expectations By $0.41 EPSBeiGene (BGNE) Posts Quarterly Earnings Results, Misses Expectations By $0.41 EPS
www.americanbankingnews.com - May 10 at 4:46 PM
BeiGene Q1 revenues $32.5MBeiGene Q1 revenues $32.5M
seekingalpha.com - May 10 at 9:40 AM
BeiGene misses by $0.33, beats on revenueBeiGene misses by $0.33, beats on revenue
seekingalpha.com - May 10 at 9:40 AM
BeiGene Reports First Quarter 2018 Financial ResultsBeiGene Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 4:32 PM
$15.84 Million in Sales Expected for BeiGene (BGNE) This Quarter$15.84 Million in Sales Expected for BeiGene (BGNE) This Quarter
www.americanbankingnews.com - May 8 at 2:29 AM
Zacks: Brokerages Anticipate BeiGene (BGNE) Will Post Earnings of -$1.96 Per ShareZacks: Brokerages Anticipate BeiGene (BGNE) Will Post Earnings of -$1.96 Per Share
www.americanbankingnews.com - May 6 at 7:33 PM
BeiGene (BGNE) Given Consensus Recommendation of "Buy" by AnalystsBeiGene (BGNE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 6 at 10:10 AM
BeiGene (BGNE) Downgraded by Zacks Investment Research to "Hold"BeiGene (BGNE) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 4 at 7:07 PM
BeiGene to Present at the Deutsche Bank 43rd Annual Health Care ConferenceBeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 4 at 4:26 PM
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
finance.yahoo.com - May 2 at 9:24 AM
BeiGene (BGNE) Upgraded to Buy by Zacks Investment ResearchBeiGene (BGNE) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 1 at 8:16 PM
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
feeds.benzinga.com - May 1 at 8:11 PM
BRIEF-BeiGene Says CEO John V. Oylers 2017 Total Compensation Was $10.3 MillionBRIEF-BeiGene Says CEO John V. Oyler's 2017 Total Compensation Was $10.3 Million
www.reuters.com - May 1 at 9:27 AM
BeiGene (BGNE) Set to Announce Quarterly Earnings on TuesdayBeiGene (BGNE) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 6:40 AM
BeiGene (BGNE) Expected to Post Quarterly Sales of $15.84 MillionBeiGene (BGNE) Expected to Post Quarterly Sales of $15.84 Million
www.americanbankingnews.com - April 21 at 2:52 AM
 Analysts Expect BeiGene (BGNE) Will Post Earnings of -$1.96 Per Share Analysts Expect BeiGene (BGNE) Will Post Earnings of -$1.96 Per Share
www.americanbankingnews.com - April 19 at 5:23 PM
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory ...BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory ...
globenewswire.com - April 16 at 4:26 PM
BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American ...BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American ...
www.reuters.com - April 16 at 4:26 PM
BeiGene (BGNE) PT Set at $200.00 by Maxim GroupBeiGene (BGNE) PT Set at $200.00 by Maxim Group
www.americanbankingnews.com - April 16 at 1:19 PM
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast ...BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast ...
globenewswire.com - April 16 at 9:20 AM
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual MeetingBeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 16 at 9:20 AM
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell LymphomasBeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
finance.yahoo.com - April 16 at 9:20 AM
Piper Jaffray Initiates Coverage on BeiGene (BGNE)Piper Jaffray Initiates Coverage on BeiGene (BGNE)
www.americanbankingnews.com - April 13 at 10:13 AM
Benzingas Top Upgrades, Downgrades For April 13, 2018Benzinga's Top Upgrades, Downgrades For April 13, 2018
www.benzinga.com - April 13 at 9:51 AM
Piper Jaffray Starts BeiGene, Ltd. (BGNE) at OverweightPiper Jaffray Starts BeiGene, Ltd. (BGNE) at Overweight
www.streetinsider.com - April 13 at 9:51 AM
These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 YearsThese 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years
finance.yahoo.com - April 13 at 9:51 AM
BeiGene (BGNE) Coverage Initiated at Ladenburg ThalmannBeiGene (BGNE) Coverage Initiated at Ladenburg Thalmann
www.americanbankingnews.com - April 13 at 12:25 AM
BeiGene (BGNE) Given Consensus Recommendation of "Buy" by BrokeragesBeiGene (BGNE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 9:38 AM
UPDATE: BeiGene, Ltd. (BGNE) PT Raised to $200 at Maxim GroupUPDATE: BeiGene, Ltd. (BGNE) PT Raised to $200 at Maxim Group
www.streetinsider.com - April 10 at 4:28 PM
BeiGene (BGNE) Price Target Raised to $200.00BeiGene (BGNE) Price Target Raised to $200.00
www.americanbankingnews.com - April 10 at 12:30 PM
BeiGene initiates Phase 2 trial of tislelizumab in patients with previously treated hepatocellular carcinomaBeiGene initiates Phase 2 trial of tislelizumab in patients with previously treated hepatocellular carcinoma
seekingalpha.com - April 10 at 8:27 AM
What Drove BeiGene Stock in March 2018?What Drove BeiGene Stock in March 2018?
finance.yahoo.com - April 9 at 4:26 PM
 Analysts Expect Beigene Ltd (BGNE) Will Announce Quarterly Sales of $16.27 Million Analysts Expect Beigene Ltd (BGNE) Will Announce Quarterly Sales of $16.27 Million
www.americanbankingnews.com - April 4 at 2:30 AM
BRIEF-BeiGene Appoints J. Samuel Su To Its Board Of DirectorsBRIEF-BeiGene Appoints J. Samuel Su To Its Board Of Directors
www.reuters.com - April 3 at 9:46 AM
BeiGene (BGNE) Names J. Samuel Su to BoardBeiGene (BGNE) Names J. Samuel Su to Board
www.streetinsider.com - April 3 at 9:46 AM
BeiGene Appoints J. Samuel Su to its Board of DirectorsBeiGene Appoints J. Samuel Su to its Board of Directors
finance.yahoo.com - April 3 at 9:46 AM
Zacks: Brokerages Anticipate Beigene Ltd (BGNE) Will Announce Earnings of -$1.94 Per ShareZacks: Brokerages Anticipate Beigene Ltd (BGNE) Will Announce Earnings of -$1.94 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM
Beigene (BGNE) Downgraded by ValuEngineBeigene (BGNE) Downgraded by ValuEngine
www.americanbankingnews.com - March 31 at 1:04 PM
Beigene (BGNE) Given a $120.00 Price Target at Maxim GroupBeigene (BGNE) Given a $120.00 Price Target at Maxim Group
www.americanbankingnews.com - March 27 at 12:39 AM

SEC Filings

BeiGene (NASDAQ:BGNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BeiGene (NASDAQ:BGNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BeiGene (NASDAQ BGNE) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.